Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA staff cautious on AstraZeneca, Bristol diabetes drug
FDA staff cautious on AstraZeneca, Bristol diabetes drug
FDA staff cautious on AstraZeneca, Bristol diabetes drug
Submitted by
admin
on December 10, 2013 - 9:21am
Source:
Yahoo/Reuters
News Tags:
FDA
AstraZeneca
Bristol-Myers Squibb
Dapagliflozin
diabetes
Headline:
FDA staff cautious on AstraZeneca, Bristol diabetes drug
Do Not Allow Advertisers to Use My Personal information
